quadraScope invests in biotech companies working to dramatically extend human healthspan by targeting the hallmarks of aging.
Hallmarks of aging
Biogerontology is the new science that aims to extend human healthspan by addressing the biological basis of aging. It revolves around the concept of the Hallmarks of Aging, a framework introduced in 2013 by LĂłpez-OtĂn et al. and further expanded in the paper Hallmarks of Aging: An Expanding Universe in 2023. The hallmarks of aging are shown below.
Genomic instability
Accumulation of DNA mutations due to failure of DNA repair mechanisms.
Telomere attrition
Shortening of the protective caps at the ends of chromosomes, leading to DNA damage and senescence.
Epigenetic alterations
Modifications in the way DNA is stored, read, and expressed, without altering the gene sequence.
Cellular senescence
Senescent cells are no loner able to divide, cannot die, and contribute to inflammation.
Mitochondrial dysfunction
Mitochondria, the energy-producing structures within cells, become leaky and inefficient.
Stem cell exhaustion
A decline in the number and function of stem cells, which are responsible for maintaining and repairing tissues.
Deregulated nutrient-sensing
Disruption of the mechanisms that control metabolism, utilization of nutrients, and energy balance.
Loss of proteostasis
Failure to maintain protein quality and function, leading to the accumulation of damaged proteins.
Disabled macroautophagy
Decreased ability to break down and recycle damaged or unnecessary cellular parts.
Altered intercellular communication
Communication systems between cells become unstable and cells lose the ability to work together effectively.
Chronic inflammation
The immune system stays persistently active even when there is no infection to fight or injury to repair.
Dysbiosis
Unbalanced populations of microorganisms that live in the human body.
Our portfolio
We have a diverse, synergetic portfolio led by serial entrepreneurs and renowned scientists.
Rejuvenation of the immune system using the secretome of immune system stem cells
Nanomachines (NaNots) that capture and remove harmful proteins from the bloodstream
Cellular rejuvenation with initial focus on facial rejuvenation and enhancement of immune cells for CAR-T therapy
Fix receding gums, facial aging, incontinence, and more via novel regenerative collagen
Enable personalized medicine and streamline drug discovery via Machine Learning platform that accurately models an individual’s state and history of health
DNA fault detection and error correction platform to diagnose, prevent, and treat diseases associated with the loss of genetic information
Treat pulmonary fibrosis and type II diabetes by boosting the immune system’s capacity to remove specific senescent cells
Cholesterol degradation platform to reverse atherosclerosis and fatty liver disease
Treating neurodegeneration, renal diseases, and other conditions by enhancing mitochondrial health through mitophagy
Drug discovery platform using human organoids subjected to accelerated aging
Franchise of clinics specializing in personalized rejuvenation treatments and offshore clinical trials
Team
We are a women-led team with a strong track record of taking new ventures from inception to profitable exits, including a 12x exit, and deep understanding of the emerging longevity science and market.
The quadraScope team is focused on the right sector, with the right team to select and vet investment opportunities. The rejuvenation industry is an emerging next wave of biotech technologies that has seen a recent surge in funding while engaging the top scientific talent.Â

Hans Keirstead, PhD
Chairman, Immunis
quadraScope’s investment allowed us to start the development of a biobetter growth hormone. This anchor investment attracted funding from two other major investors.

Robert (Bobby) Brooke
CEO, Intervene Immune
quadraScope has been a sounding board and a strong source of encouragement and support for our strategic direction.

Tom Benson, PhD
CEO, Mitrix Bio
quadraScope is tapping the fast-emerging rejuvenation market with an abundance of research ready to be commercialized. With their strategic locations in Boston and Tel-Aviv they are poised to leverage the high concentration of biotech academia, industry and talent pool.

Reason
CEO, Repair Biotechnologies
We chose to partner with Quadrascope because of the strategic alignment of our visions, namely the importance of investment in programs that extend life-span and health-span while at the same time applying the same science to treat diseases that have no treatment.

Menachem Abraham
CEO, Klogenix
quadraScope, our first investor, has encouraged the formation of rejuvenation clinics and has been active in defining the treatment protocols as a strategic pillar alongside clinical trials.
